Interested in more on JPMorgan Chase? See TheStreet Ratings' report card for this stock. -- Written by Philip van Doorn in Jupiter, Fla. >Contact by Email. Follow @PhilipvanDoorn
The advisers stand to benefit if the sector sees more deal activity under Trump.
Doug Kass shares his thoughts on biotech, and discusses the shape of things to come.